Can you receive the quadrivalent HPV vaccine if infected with HPV type 58?

HPV refers to human papillomavirus. Whether individuals infected with HPV type 58 can receive the quadrivalent HPV vaccine remains somewhat controversial. However, based on current evidence, for most people, vaccination is still possible after infection with HPV type 58 and can provide immune benefits. Nevertheless, if there is persistent infection or the individual belongs to a group contraindicated for the quadrivalent HPV vaccine, vaccination is not recommended to avoid potential complications. Detailed analysis is as follows:

The quadrivalent vaccine is approved for individuals aged 9–45 years and primarily prevents HPV types 6, 11, 16, and 18. HPV type 58 is classified as a high-risk type and is not covered by the quadrivalent vaccine. Therefore, if an individual does not have allergies to vaccine components and is not in a special population group, remaining within the eligible age range, they can generally proceed with quadrivalent HPV vaccination. This provides protection against other HPV types and helps prevent additional unknown infections.

However, if an individual is found to have persistent HPV type 58 infection that has not been cleared, particularly when accompanied by compromised immunity, cervical intraepithelial neoplasia, or cervical cancerous changes, receiving the quadrivalent HPV vaccine is unnecessary and offers little clinical benefit.

Patients infected with HPV type 58 may receive the quadrivalent vaccine unless they are allergic to any of its components, in which case vaccination is not advised to prevent hypersensitivity reactions.

It should be noted that HPV is infectious, so appropriate preventive measures must be taken to avoid cross-infection. Additionally, individuals infected with HPV should undergo regular monitoring. If any symptoms or abnormalities occur, prompt medical attention is essential to minimize the risk of malignant transformation.